Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.
CKD · dialysis · CRRT
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney dosing for each component (single-agent) is shown under Component information.
Kidney-specific guidance from renalcarematters.com: in preparation.
Parenteral nutrition · CKD · AKI · KRT
Parenteral nutrition: kidney notes
Brand-specific kidney notes for the parenteral nutrition products filed under this generic: composition from the manufacturer SmPC or package insert, its kidney-related text, and how the product fits the guideline. Sources are listed under References.
SmofKabiven Central (Fresenius Kabi AB) is a three-chamber bag of amino acids with electrolytes, glucose and SMOFlipid (soybean oil, medium-chain triglycerides, olive oil and fish oil) for central-vein parenteral nutrition. The Philippine registration is the 1970 ml bag. It is a standard formula containing potassium, phosphate and magnesium.
Composition
Per presentation
1970 ml bag
per 1000 ml
Amino acids (g)
100
51
Nitrogen (g)
16
8
Lipid (g)
75
38
Glucose (g)
250
127
Energy, total, approx. (kcal)
2200
1100
Energy, non-protein, approx. (kcal)
1800
900
Sodium (mmol)
80
41
Potassium (mmol)
60
30
Magnesium (mmol)
10
5.1
Calcium (mmol)
5
2.5
Phosphate (mmol)
25
13
Zinc (mmol)
0.08
0.04
Sulfate (mmol)
10
5.1
Chloride (mmol)
70
36
Acetate (mmol)
209
106
Osmolality approximately 1800 mosmol/kg water; osmolarity approximately 1500 mosmol/l (SmPC section 3).
Composition from the Irish (EU) SmPC; the Philippine package insert was not available to compare.
Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.
Dose and rate limits
Infusion rate should not exceed 2.0 ml/kg body weight per hour; maximum daily dose 35 ml/kg body weight per day (SmPC 4.2).
Kidney notes
Contraindicated in "severe renal insufficiency without access to hemofiltration or dialysis" and with pathologically elevated serum levels of any of the included electrolytes (SmPC 4.3).
In patients with renal insufficiency, phosphate and potassium intake should be carefully controlled to prevent hyperphosphatemia and hyperkalemia (SmPC 4.4).
Give with caution in impaired lipid metabolism, which may occur in renal failure, and to patients with a tendency towards electrolyte retention; correct fluid and electrolyte disturbances before starting (SmPC 4.4).
The lipid emulsion (SMOFlipid) contains fish oil; see ESPEN Recommendation 27 on omega-3-enriched PN in kidney disease.
How it fits the ESPEN 2021 kidney nutrition guideline
ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
ESPEN 2021 Recommendation 29: "Serum glucose levels shall be maintained between 140–180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with KF." Grade of recommendation A – Strong consensus (95.5% agreement). Recommendation 30: "Tight glucose control (80–110 mg/dl) shall not be pursued because of the increased risk of hypoglycemia." Grade of recommendation A – Strong consensus (100% agreement).
ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)
ESPEN 2021 Recommendation 27: "There is not enough evidence to support the routine use of omega-3 polyunsaturated fatty acids (PUFA) supplements or PN solutions enriched with omega-3 PUFA in hospitalized patients with AKI, AKI on CKD or CKD with KF." Grade of recommendation GPP – Strong consensus (95.8% agreement).
Bottom line
A standard central three-chamber bag with a mixed-oil lipid. In severe renal insufficiency it needs dialysis or hemofiltration access, and its 60 mmol potassium and 25 mmol phosphate per 1970 ml bag must be counted. Choose by calorie-to-protein ratio, not by brand, and monitor electrolytes closely.
Not shown here
Phosphate for the 493 ml and 986 ml bags (out of pattern in the fetched text; these sizes are not registered in the Philippines).
renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed
Kidney notes: SmofKabiven Peripheral
SmofKabiven Peripheral (Fresenius Kabi AB) is a lower-osmolarity three-chamber bag of amino acids with electrolytes, glucose and SMOFlipid for peripheral or central infusion. Philippine registrations: 1206, 1448 and 1904 ml bags. It is a standard formula containing potassium and phosphate.
Composition
Per presentation
1206 ml bag
1448 ml bag
1904 ml bag
per 1000 ml
Amino acids (g)
38
46
60
32
Nitrogen (g)
6.2
7.4
9.8
5.1
Lipid (g)
34
41
54
28
Glucose (g)
85
103
135
71
Energy, total (kcal)
800
1000
1300
700
Energy, non-protein (kcal)
700
800
1100
600
Sodium (mmol)
30
36
48
25
Potassium (mmol)
23
28
36
19
Magnesium (mmol)
3.8
4.6
6
3.2
Calcium (mmol)
1.9
2.3
3
1.6
Phosphate (mmol)
9.9
11.9
15.6
8.2
Zinc (mmol)
0.03
0.03
0.05
0.02
Sulfate (mmol)
3.8
4.6
6.1
3.2
Chloride (mmol)
27
32
42
22
Acetate (mmol)
79
96
125
66
Osmolality approximately 950 mosmol/kg water; osmolarity approximately 850 mosmol/l (SmPC section 3).
Phosphate: contribution from both the lipid emulsion and the amino acid solution (SmPC section 2, footnote).
Composition from the Irish (EU) SmPC; the Philippine package insert was not available to compare.
Composition from the cited manufacturer SmPC/package insert; values independently re-checked November 17, 2026.
Dose and rate limits
Infusion rate should not exceed 3.0 ml/kg body weight per hour; maximum daily dose 40 ml/kg body weight per day (SmPC 4.2).
Kidney notes
Contraindicated in "severe renal insufficiency without access to hemofiltration or dialysis" and with pathologically elevated serum levels of any of the included electrolytes (SmPC 4.3).
In patients with renal insufficiency, phosphate and potassium intake should be carefully controlled to prevent hyperphosphatemia and hyperkalemia (SmPC 4.4).
Give with caution in impaired lipid metabolism, which may occur in renal failure, and to patients with a tendency towards electrolyte retention; correct fluid and electrolyte disturbances before starting (SmPC 4.4).
The lipid emulsion (SMOFlipid) contains fish oil; see ESPEN Recommendation 27 on omega-3-enriched PN in kidney disease.
How it fits the ESPEN 2021 kidney nutrition guideline
ESPEN 2021 Recommendation 18 (Grade of recommendation 0 – Consensus (82.6% agreement)): protein intakes that may be prescribed are 0.6–0.8 g/kg body weight (BW)/d for a hospitalized patient with CKD without acute/critical illness; 1.2 g/kg BW/d with CKD and KF on conventional intermittent chronic KRT without acute/critical illness; 0.8–1.0 g/kg BW/d with AKI or AKI on CKD without acute/critical illness; start with 1 g/kg BW/day and gradually increase up to 1.3 g/kg BW/d if tolerated with acute/critical illness not on KRT; 1.3–1.5 g/kg/d for critically ill patients on conventional intermittent KRT; and 1.5 g/kg/d up to 1.7 g/kg/d for critically ill patients on continuous KRT (CKRT) or prolonged intermittent KRT (PIKRT). "If available, the pre-hospitalization body weight or usual body weight may be preferred over the ideal BW. Actual BW should not be considered for a protein prescription." (AKI, acute kidney injury.)
ESPEN 2021 Recommendation 25: "The choice of the most appropriate EN or PN formula should be made based on the calorie and protein ratio to provide the most accurate dosing in clinical practice." Grade of recommendation B – Strong consensus (91.3% agreement). (PN, parenteral nutrition.)
ESPEN 2021 Recommendation 24: "No disease-specific enteral nor parenteral formula oriented for patients with reduced kidney function should be routinely utilized in every patient with AKI, AKI on CKD, or CKD with KF in comparison to conventional formulas. Instead, their use is to be individualized (see recommendation 26)." Grade of recommendation B – Consensus (87.5% agreement).
ESPEN 2021 Recommendation 26: "In selected patients with electrolyte and fluid imbalances, concentrated “renal” EN or PN formulas with lower electrolyte content may be preferred over standard formulas." Grade of recommendation GPP – Strong consensus (95.7% agreement). (GPP, good practice point.)
ESPEN 2021 Recommendation 31: "Electrolytes abnormalities are common in patients with AKI, AKI on CKD, or CKD with KF receiving KRT and shall be closely monitored." Grade of recommendation A – Strong consensus (100% agreement).
ESPEN 2021 Recommendation 29: "Serum glucose levels shall be maintained between 140–180 mg/dl in hospitalized patients with AKI, AKI on CKD, or CKD with KF." Grade of recommendation A – Strong consensus (95.5% agreement). Recommendation 30: "Tight glucose control (80–110 mg/dl) shall not be pursued because of the increased risk of hypoglycemia." Grade of recommendation A – Strong consensus (100% agreement).
ESPEN 2021 Recommendation 14: "For patients undergoing KRT, the total energy provision by additional calories given in the form of citrate, lactate, and glucose from dialysis/hemofiltration solutions should be included in the calculations to determine the total daily energy provision to avoid overfeeding." Grade of recommendation B – Strong consensus (100% agreement). (KRT, kidney replacement therapy.)
ESPEN 2021 Recommendation 4: "Intradialytic parenteral nutrition (IDPN) shall be applied in malnourished non-critically ill hospitalized patients with CKD and KF on hemodialysis, or the same patients if at risk of malnutrition that fail to respond or do not tolerate ONS or EN." Grade of recommendation A – Strong consensus (91.7% agreement). (CKD, chronic kidney disease; KF, kidney failure; ONS, oral nutritional supplements; EN, enteral nutrition.)
ESPEN 2021 Recommendation 27: "There is not enough evidence to support the routine use of omega-3 polyunsaturated fatty acids (PUFA) supplements or PN solutions enriched with omega-3 PUFA in hospitalized patients with AKI, AKI on CKD or CKD with KF." Grade of recommendation GPP – Strong consensus (95.8% agreement).
Bottom line
A standard peripheral three-chamber bag with a mixed-oil lipid. In severe renal insufficiency it needs dialysis or hemofiltration access; count its potassium and phosphate and its volume, and monitor electrolytes closely.
renalcarematters.com notes, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Check the current Philippine package insert before use. renalcarematters.com, reviewed
Dosage forms
Philippines
Emulsion for i.v. infusion
Emulsion for iv infusion
Emulsion for intravenous infusion
Philippine products
Registered products in the Philippines
5 products registered with the Food and Drug Administration (FDA) Philippines list
Amino acids + Electrolytes + Glucose + Lipid emulsion as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Emulsion for Intravenous Infusion (IV)1,540 mL Polypropylene 3‐Chamber Bag in Plastic Overpouch (Box of 4's); 2,053 mL Polypropylene 3‐Chamber Bag in Plastic Overpouch (Box of 2's)
Emulsion for I.V. Infusion1,440 mL Polypropylene 3-Chamber Bag in Plastic Overpouch (Box of 4's); 1,920 mL Polypropylene 3-Chamber Bag in Plastic Overpouch (Box of 2's); 384 mL Polypropylene 3-Chamber Bag in Plastic Overpouch (Box of 8's)
Emulsion for IV Infusion (See reverse for formulation)Biofine three-chamber bag (1206 mL in box of 4's; 1448 mL in box of 4's; 1904 mL in box of 4's); Biofine three-chamber bag (1206 mL in box of 1's; 1448 mL in box of 1's; 1904 mL in box of 1's)
Rx
Fresenius Kabi ABSweden
Importer: Fresenius Kabi Philippines, Inc.
DR-XY40842
Apr 6, 2031
No products match these filters.
Source: FDA Philippines product registration database. "Valid until" is the registration validity date
listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Fiaccadori, E., Sabatino, A., Barazzoni, R., Carrero, J. J., Cupisti, A., De Waele, E., Jonckheer, J., Singer, P., & Cuerda, C. (2021). ESPEN guideline on clinical nutrition in hospitalized patients with acute or chronic kidney disease. Clinical Nutrition, 40(4), 1644–1668. https://doi.org/10.1016/j.clnu.2021.01.028
renalcarematters.com content: Parenteral nutrition kidney notes (SmofKabiven Central): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Parenteral nutrition kidney notes (SmofKabiven Peripheral): reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.